BRPI0923249A2 - uso de modulinas solúveis em fenol no desenvolvimento de vacinas - Google Patents

uso de modulinas solúveis em fenol no desenvolvimento de vacinas

Info

Publication number
BRPI0923249A2
BRPI0923249A2 BRPI0923249A BRPI0923249A BRPI0923249A2 BR PI0923249 A2 BRPI0923249 A2 BR PI0923249A2 BR PI0923249 A BRPI0923249 A BR PI0923249A BR PI0923249 A BRPI0923249 A BR PI0923249A BR PI0923249 A2 BRPI0923249 A2 BR PI0923249A2
Authority
BR
Brazil
Prior art keywords
vaccine development
phenol soluble
soluble modulins
modulins
phenol
Prior art date
Application number
BRPI0923249A
Other languages
English (en)
Inventor
Claude Leclerc
Francisco Borrás Cuesta
Inés Noelia Casares Lagar
Jesús María Prieto Valtueña
Juan José Lasarte Sagastibelza
María Del Carmen Delgado Durántez
Pablo Sarobe Ugarriza
Original Assignee
Inst Pasteur Ct Nat De La Rech Scient Cnrs
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Pasteur Ct Nat De La Rech Scient Cnrs, Proyecto Biomedicina Cima Sl filed Critical Inst Pasteur Ct Nat De La Rech Scient Cnrs
Publication of BRPI0923249A2 publication Critical patent/BRPI0923249A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
BRPI0923249A 2008-12-03 2009-12-02 uso de modulinas solúveis em fenol no desenvolvimento de vacinas BRPI0923249A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200803441 2008-12-03
PCT/ES2009/070546 WO2010063865A1 (es) 2008-12-03 2009-12-02 Uso de modulinas solubles en fenol para el desarrollo de vacunas

Publications (1)

Publication Number Publication Date
BRPI0923249A2 true BRPI0923249A2 (pt) 2016-01-26

Family

ID=42072810

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923249A BRPI0923249A2 (pt) 2008-12-03 2009-12-02 uso de modulinas solúveis em fenol no desenvolvimento de vacinas

Country Status (9)

Country Link
US (1) US20110268757A1 (pt)
EP (1) EP2374813A1 (pt)
JP (1) JP2012510284A (pt)
CN (1) CN102325790A (pt)
AU (1) AU2009323996A1 (pt)
BR (1) BRPI0923249A2 (pt)
CA (1) CA2745603A1 (pt)
MX (1) MX2011005915A (pt)
WO (1) WO2010063865A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089602A1 (en) * 2016-11-09 2018-05-17 Baylor College Of Medicine Therapeutic for the prevention and/or treatment of weight gain and/or diabetes
JP7373176B2 (ja) * 2017-08-31 2023-11-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚の酵素活性を制御する分子的細菌療法
CN112778399A (zh) * 2021-01-21 2021-05-11 南开大学 一类源自毒性淀粉样纤维纳米抗菌肽的制备及性质表征方法
CN113234125B (zh) * 2021-05-10 2022-12-06 华东理工大学 自组装多肽、多肽水凝胶及其制备方法和用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5081029A (en) 1985-09-25 1992-01-14 Oncogen Methods of adoptive immunotherapy for treatment of aids
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
ATE124866T1 (de) 1991-01-16 1995-07-15 Schering Corp Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
US6005099A (en) 1993-11-17 1999-12-21 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6274378B1 (en) 1997-10-27 2001-08-14 The Rockefeller University Methods and compositions for obtaining mature dendritic cells
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
RU2223262C2 (ru) 1998-06-30 2004-02-10 Ом Фарма Новые ацилированные псевдодипептиды, способ их получения и содержащие их фармацевтические композиции
US6809186B1 (en) 1999-01-22 2004-10-26 Martek Biosciences Corporation Simple method for labeled conjugate production
FR2819263B1 (fr) 2001-01-10 2003-04-11 Lco Sante Procede de maturation des cellules dendritiques et d'activation des macrophages avec le ru 41740
CA2444130C (en) 2001-04-17 2010-12-21 Sumitomo Pharmaceuticals Company, Limited Adenine derivatives
DE60230340D1 (de) 2001-11-16 2009-01-22 3M Innovative Properties Co N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
WO2004054622A1 (en) 2002-12-13 2004-07-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
CA2511538C (en) 2002-12-30 2013-11-26 3M Innovative Properties Company Immunostimulatory combinations
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20050255042A1 (en) 2003-11-24 2005-11-17 The Regents Of The University Of California Office Of Technology Transfer, University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
WO2006107617A2 (en) 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
RU41740U1 (ru) 2004-07-16 2004-11-10 Колесник Владислав Иванович Набережная
DE602005025005D1 (de) 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
CA2596248A1 (en) 2005-01-31 2006-08-10 Vaxinnate Corporation Method to identify polypeptide toll-like receptor (tlr) ligands
ES2291071B1 (es) 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
PT1949913E (pt) 2005-10-07 2010-08-24 Proyecto Biomedicina Cima Sl Associação imunoestimuladora para a profilaxia e o tratamento da hepatite c
CA2607056C (en) 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
TW200745158A (en) 2006-03-07 2007-12-16 Vaxinnate Corp Compositions that include hemagglutinin, methods of making and methods of use thereof
US20100166708A1 (en) * 2007-02-20 2010-07-01 The Regents Of The University Of California Antimicrobial and anti-inflammatory therapies and compositions

Also Published As

Publication number Publication date
AU2009323996A1 (en) 2011-07-07
EP2374813A1 (en) 2011-10-12
CN102325790A (zh) 2012-01-18
WO2010063865A1 (es) 2010-06-10
CA2745603A1 (en) 2010-06-10
US20110268757A1 (en) 2011-11-03
MX2011005915A (es) 2011-08-17
JP2012510284A (ja) 2012-05-10

Similar Documents

Publication Publication Date Title
BRPI0813947A2 (pt) Uso de estriol em baixas doses
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BR112013008410A2 (pt) sistema para uso em reparação tecidual
BRPI0911297A2 (pt) composição e métodos para preparo e uso das mesmas
BRPI0909770A2 (pt) Vacina, e, kit
BR112012002349A2 (pt) composto,e, uso do mesmo
BR112012013148A2 (pt) formulação farmacêutica e uso
UY33132A (es) Proteínas solubles para su uso terapéutico
BRPI0821668A2 (pt) Uso
BRPI0911563A2 (pt) uso de antagonista da progesterona
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI0917535A2 (pt) uso de insulina de ação ultra rápida
BRPI0719929A2 (pt) Partículas que compreendem um siloxano fluorado e métodos de preparo e uso das mesmas
BR112012003445A2 (pt) aparelho dental sem o uso das maos para limpeza dos dentes
BRPI1012861A2 (pt) catalisador, e, uso do catalisador
DK2200646T3 (da) RNA-Vacciner
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI0915086A2 (pt) detecção do uso de canabis
FI20086250A (fi) Sieniendoglukanaasit, niiden valmistus ja käyttö
BRPI0917205A2 (pt) vacina polivalente
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
BRPI0919794A2 (pt) dispositivo para uso intracorpóreo, e, composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2372 DE 21-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.